Oncomine NGS Solutions for Hemato-oncology Research

Unlocking more blood cancer insights with NGS

Each year, an estimated 1.28 million people are diagnosed with a blood cancer, accounting for roughly 6% of all new cancer cases worldwide1.

 

These challenging disorders are genetically complex, often harboring a range of somatic mutations. In recent years, studies have uncovered a multitude of disease-associated genetic alterations that are fueling precision-oncology research and progressing hope for a better future in managing these diseases.

hemato-oncology couple

Benefit of NGS for hemato-oncology research

Traditional molecular testing involves iterative single-analyte approaches, complex workflows, all of which results in variable, often lengthy, turnaround times.

 

Next-generation sequencing (NGS) has revolutionized the study of  hematologic malignancies by streamlining genetic profiling. NGS allows for efficient, simultaneous assessment of multiple genetic biomarkers with a single assay. Advancements in NGS automation enable results in as few as 1-2 days.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Hemato-oncology research NGS solutions

      Deepen your understanding of hematological malignancies with an unmatched offering of NGS testing solutions and capabilities. We offer a range of NGS assays for applications across a spectrum of disease research areas. Each assay is provided as part of a complete solution on our trusted NGS platforms, the Ion GeneStudio S5 System and the Ion Torrent Genexus System.


      Integrated analysis software streamlines reporting and facilitates the interpretation of results. Unmatched workflow automation simplifies the testing process, enabling any laboratory to adopt NGS testing—including those without prior experience and expertise.

      Oncomine Myeloid Assays GX v2

      myeloid gx

      Oncomine Myeloid MRD Assays (RUO)

      Myeloid MRD Assays

      Oncomine Immune Repertoire Assays

      Immune Repertoire Assays

      Customer presentations

      Moving toward a brighter future in hemato-oncology 

      Our customers and collaborators are making incredible research advancements, disrupting traditional paradigms, and bringing forth new insights and approaches for understanding hematologic malignancies. Our NGS technology has been embraced by some of the top minds in the world to address the most pressing challenges is these disease research areas.

      Implementing NGS for the Study of Lymphoid Malignancies

      Gerard Frigola, MD

      Hematopathologist
      Hospital Clinic, IDIBAPS,
      University of Barcelona

      2024 AACR Poster

      AMP 2023 Workshop On-Demand: NGS for Myeloid Malignancy Analysis

      Cecilia Yeung, MD

      Professor, Translational Science and Therapeutics Division
      Medical Director, Fred Hutch Clinical Testing Labs
      Fred Hutchinson Cancer Center

      Cecilia Yeung

      Utility of NGS in Lymphoid Malignancies

      Dr. Michael Krigstein

      Consultant Haematologist
      MBBS(Hons) FRACP FRCPA MCncrSc
      SydPath, St Vincent’s Hospital

      Michael Krigstein

      The Time is Now for NGS-Based Clonality Testing

      Dr. Michael Hummel

      Charite

      Michael Hummel

      NGS for B Cell Receptor Sequencing in Multiple Myeloma

      Dr. Arthur Kowalik

      Holy Cross Cancer Center

      Arthur Kowalik

      Lymphoma Molecular Characterization - Assessing the Journey to Answers

      Dr. Marianne Grantham

      Barts Health NHS Trust

      Marianne Grantham

      Advances in Immune Repertoire Sequencing for the Study of Lymphoid Neoplasm

      Dr. John DeCoteau

      Professor of Pathology & Laboratory Medicine, Medical Director, Advanced Diagnostic Research Laboratory, University of Saskatchewan

      John DeCoteau

      How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms

      Dr. Bevan Tandon

      Director of Hematopathology
      and Molecular Pathology,
      Pathline Labs

      Bevan Tandon

      Molecular Analysis in the Diagnosis and Prognosis of Hematological Malignancies

      Dr. Geetha Menon

      Clinical Director
      HODS, Cheshire & Merseyside Cancer Network, Liverpool Clinical Laboratories.

      Geetha Menon

      Ready to speak to a Thermo Fisher representative?

      We will be happy to answer your questions and provide a demo of our NGS solutions.

      For Research Use Only. Not for use in diagnostic procedures.